In this edition of Ask An SEO, we break down a common point of confusion for site owners and technical SEOs: Do I need both an XML sitemap and an HTML one, and which one is better to use for SEO? It ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

This is a bit loaded question as if you're looking at this page, it's rendered from (X)HTML = XML. But what I am interested in (for a talk / research topic) is if people are still choosing (directly ...

XML sitemaps may sound technical, but they’re very simple, often auto-generated within content management systems (CMS), and essential for achieving SEO success. Without a sitemap, you’re relying ...

TIOBE Programming Index News August 2025: AI Copilots Are Boosting Python’s Popularity Your email has been sent Generative AI can be a self-fulfilling prophecy: Because gen AI scans vast amounts of ...

A reptile hunter sprang into action last week to remove a 16-foot python that was slithering around a dumpster at a Los Angeles apartment building. Dramatic video shows 24-year-old Joseph Hart — ...

LOS ANGELES (KABC) -- What would you do if you found a 20-foot python in your apartment complex's dumpster? Well, that's exactly what happened Tuesday in Los Angeles. Joseph Hart - who's known as the ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...